Icra sees pharma industry growth tapering to 7-10% over FY18-FY20Post published:July 4, 2017Post category:Industry NewsThe Indian pharma industry is likely to witness a slowdown in growth because of pricing pressure and regulatory interventions in the US, according to an Icra report Source: Livemint.com (http://www.livemint.com/rss/industry)Read more articles Previous PostIndoStar Capital close to acquiring ICICI Home Finance Next PostGST rates: Footwear to cost more as firms look to increase prices by 5-7% You Might Also Like Indian Oil to receive first-ever US crude import in October July 10, 2017 StratEdge announces Reginald (Regi) Nocom joins company as process engineer January 14, 2020 iDTRONIC releases Embedded HF Mid-Range M500 module January 19, 2019